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Abstract
Background: Chromatin adapts and responds to extrinsic and intrinsic cues. We hypothesize that inheritable aberrant
chromatin states in cancer and aging are caused by genetic/environmental factors. In previous studies we demonstrated
that either genetic mutations, or loss, of retinoic acid receptor alpha (RARa), can impair the integration of the retinoic acid
(RA) signal at the chromatin of RA-responsive genes downstream of RARa, and can lead to aberrant repressive chromatin
states marked by epigenetic modifications. In this study we tested whether the mere interference with the availability of RA
signal at RARa, in cells with an otherwise functional RARa, can also induce epigenetic repression at RA-responsive genes
downstream of RARa.
Methodology/Principal Findings: To hamper the availability of RA at RARa in untransformed human mammary epithelial
cells, we targeted the cellular RA-binding protein 2 (CRABP2), which transports RA from the cytoplasm onto the nuclear
RARs. Stable ectopic expression of a CRABP2 mutant unable to enter the nucleus, as well as stable knock down of
endogenous CRABP2, led to the coordinated transcriptional repression of a few RA-responsive genes downstream of RARa.
The chromatin at these genes acquired an exacerbated repressed state, or state ‘‘of no return’’. This aberrant state is
unresponsive to RA, and therefore differs from the physiologically repressed, yet ‘‘poised’’ state, which is responsive to RA.
Consistent with development of homozygosis for epigenetically repressed loci, a significant proportion of cells with a
defective CRABP2-mediated RA transport developed heritable phenotypes indicative of loss of function.
Conclusion/Significance: Derangement/lack of a critical factor necessary for RARa function induces epigenetic repression of
a RA-regulated gene network downstream of RARa, with major pleiotropic biological outcomes.
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Introduction
Retinoic acid (RA), the bioactive derivative of retinol, is a signal
fundamental for developmental and cellular processes, whose
intracellular physiological level is tightly regulated by a complex
metabolic pathway involving both RA synthesis and RA catabolism
[1,2]. RA exerts its biological action mainly by binding and activating
specialized transcription factors, the RA-receptors (RARs) [3]. When
RA is channeled onto the retinoic acid receptor alpha (RARa)i nt h e
nucleus, it can rapidly induce transcription of RARa-target genes
containing a RA-responsive element (RARE). Specifically, RA
binding to RARa triggers both the dissociation of corepressors
proteins, and the recruitment of coactivators and histone modifying
enzymes that enable chromatin conformation changes compatible
with the access and action of RNA polymerase II [4,5].
The temporal dynamics of the cascade of events following RA-
RARa-mediated chromatin activation has been mostly derived
from studies on the prototypic direct RARa-target gene RARb2.
Once expressed in response to RA, RARb2 sustains its own
transcription by binding to its own promoter [6], and subsequently
activates the chromatin of other downstream RA-responsive direct
target genes [7,8]. In the absence of RA, RARb2 chromatin reaches
a repressed state, which is however poised for transcription [4,5].
Previously, we demonstrated that when RA signal cannot be
integrated at RARa, because RARa is either not expressed, or has
acquired genetic mutations that make it non-functional, the
chromatin associated with RARb2 falls into an aberrant exacerbated
state of repression, which is unresponsive to RA [9]. Moreover, by
using different cell systems, we demonstrated that the impaired
integrationofRA signal ata mutant RARainduces a repressionwave
that is propagated, in a domino fashion, from RARb2 to targets
downstream of RARb2. Specifically, by using mouse embryocarci-
n o m ac e l l s ,w ef o u n dt h a tad o m i n a n tn e g a t i v eR A R a mutantcreates
a concerted repression of both RARb2 and its direct target CYP26A1,
encoding the cytochrome P450 RA-specific hydrolase, which acts as a
neuronal differentiation switch in these cells [8,10]. In an
independent study using human mammary epithelial cells, we
demonstrated that inhibition of RARa function with various genetic
strategies triggers the concerted repression of both RARb2 and
another target downstream of RARb2, CRBP1, encoding the cellular
retinol binding protein 1, which is pivotal for breast epithelial cell
acinar morphogenesis [7].
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4305Based on the observation that the RARb2 chromatin can also be
found aberrantly repressed in RARa-positive cancer cells [11], we
hypothesized that lack/derangement of upstream factors capable
of affecting RARa function is sufficient to induce aberrant
chromatin repression at RARb2 and its downstream targets.
In the present study we show that the derangement of the
cellular RA binding protein 2 (CRABP2), critical for the transport
of RA from the cytoplasm to the RARs in the nucleus [12], can
indeed trigger a long-distance chromatin repression effect at loci of
an entire RARa-regulated epigenetic network. We found that, not
only the knock down of endogenous CRABP2 by RNAi, but
simply the mere interference of RA transport into the nucleus,
achieved by expressing a dominant negative CRABP2 mutant
unable to enter the nucleus [13], can initiate the wave of aberrant
repression at the chromatin of multiple RA-responsive genes. The
wave of repression involves first RARb2, thus affecting cell growth,
and next branches downstream, to involve genes that control both
RA metabolism/homeostasis and morphogenesis.
In conclusion, interference with RA transport at RARa into the
nucleus is sufficient to induce coordinated, heritable, chromatin
repression at multiple loci of a RA-responsive gene network
downstream of RARa, with pleiotropic biological outcomes.
Results
Interference with RA transport into the nucleus is
sufficient to induce transcriptional repression of genes
downstream of RARa
RARa activation requires the transport of RA to RARa in the
nucleus by CRABP2 [12,14,15]. HME1 cells, which express both
RARa (Fig. 1A left) and CRABP2 (Fig. 1A, right), can properly
integrate RA signal through RARa, as demonstrated by the
transcriptional activation of two prototypic RA-responsive
genes, RARb2, a downstream RARa target, and CRBP1,a
downstream RARb2 target (Fig. 1B, left and right).
To transport RA into the nucleus, CRABP2 requires a specific
nuclear localization signal (NLS) [13]. A mutant CRABP2-KRK
protein, which was shown to bindRA with affinity similar to the one
of the wild type CRABP2 protein, cannot transport RA into the
nucleus due to critical mutations in the NLS [13]. Indeed, by using
immunocytochemistry, we found that the V5-tagged CRABP2-
KRK protein, transiently expressed in HME1 cells, differently from
the wild type CRABP2-V5 protein, is not able to enter the nucleus
after addition of RA (0.1 mM, 30 minutes) (Fig. 1C).
Next, we tested whether RA transport into the nucleus is
hampered in CRABP2-KRK-positive cells. Stable expression of
the CRABP2-KRK-V5 protein in HME1 cells (shown for the
KRK-15 clone in Fig. 1D, left), while not affecting the expression
of endogenous RARa relative to the control clone EV7 (Fig. 1D,
right), clearly exerts a dominant negative effect over the
endogenous CRABP2. This conclusion is based on the observation
that RA-induced transcriptional activation of both RARb2 and
CRBP1 is reduced in the KRK-15 clone relative to the control
clone EV7 (Fig. 1E, left and right). Thus, targeting CRABP2
function prevents RARa function and affects, in a negative and
irreversible fashion, the transcriptional status of RA-responsive
genes downstream of RARa.
Evidence of chromatin repression at RA-responsive genes
downstream of RARa consequent to CRABP2 knock-
down
To test whether targeting endogenous CRABP2 in HME1 cells
can indeed induce heritable aberrant repression of the chromatin at
both RARb2 and CRBP1, we knocked down CRABP2 by stable
RNA interference with either one of two CRABP2-targeting shRNA
sequences, CRABP2-A and CRABP2-C (Fig. S1A). A scrambled
(mock) shRNA sequence, which should not recognize any human
mRNA, was used as a control (Fig. S1A). Only the shRNAs
sequences directed against CRABP2 were shown to efficiently
decrease exogenous CRABP2 protein expression (Fig. S1B).
We further tested two CRABP2 knock down clones, Si-
CRABP2-A6, carrying the CRABP2-A sequence, and Si-
CRABP2-C6, carrying the CRABP2-C sequence, along with the
control clone Mock13, carrying the scrambled sequence (Fig.
S1C). Both Si-CRABP2-A6 and Si-CRABP2-C6 displayed a
significant decrease of the CRABP2 transcript (Fig. 2A, left), while
they still expressed the RARa receptor (Fig. 2A, right). RA failed
to activate the transcription of both RARb2 and CRBP1 in both
knock down clones (Fig. 2B, left and right).
Moreover, ChIP analysis with anti-acetylated histone H4 (Ac-
H4) showed significant hypoacetylation, which remained unre-
sponsive to RA, of the chromatin regions encompassing either the
RARb2-RARE or the CRBP1-RARE (Fig. 2C, top and bottom).
Apparently, the chromatin at both RARb2 and CRBP1 was
converted from a state poised for transcription to an exacerbated
repressed state unresponsive to RA, which could be reverted only
by treatment with the HDAC inhibitor Trichostatin A (TSA)
(Fig. 2D, top and bottom). This conclusion was consistent with
ChIP analysis with an anti-RNA Polymerase II (Pol II) antibody
showing that both RARb2-RARE and CRBP1-RARE chromatin
regions have become inaccessible to RNA Polymerase II (Fig. 2E,
top and bottom).
Thus, as a consequence of CRABP2 knock down, the chromatin
of two loci downstream of RARa has acquired a repressed ‘‘state of
no return’’, unresponsive to RA. This state, non-permissive for
transcription, differs from the poised state, responsive to RA,
which is permissive for transcription.
Hampering CRABP2 function in HME1 cells leads to
biological phenotypes that reflect homozygosis for
epigenetically silent RARb2 and CRBP1 alleles
We previously demonstrated that knock down of the tumor
suppressor RARb2 in HME1 cells confers resistance to RA-
induced growth inhibition [7] (Fig. 3A, left). Analysis of RA-
resistance by colony formation in HME1-derived clones with
either ectopic expression of CRABP2-KRK (CRABP2-KRK15),
or CRABP2 knock down (Si-CRABP2-A6 and Si-CRABP2-C6)
(Fig. 3A, right) clearly indicated loss of RARb2 function. RA-
resistance is expected only in association with homozygous
repression of the chromatin at RARb2 alleles, which are
consequently non permissive (np) for transcription (Fig. 3B).
Similarly, we previously demonstrated that CRBP1 knock down in
HME1 cells hampers acinar morphogenesis in 3D culture [7]
(Fig. 3C). We observed aberrant acinar morphology also in
HME1-derived clones with either ectopic expression of CRABP2-
KRK (CRABP2-KRK15) or CRABP2 knock down (Si-CRABP2-
A6 and Si-CRABP2-C6) (Fig. 3C), thus indicating loss of CRBP1
function. Loss of proper acinar morphogenesis is expected only in
association with homozygous repression of the chromatin at
CRBP1 alleles, which are consequently non permissive (np) for
transcription (Fig. 3D).
Interference with CRABP2 function apparently induces loss of
both RA-induced growth inhibition and 3D-acinar morphogenesis
in a significant fraction of cells, strongly suggesting the occurrence
of heritable homozygous epigenetic silencing at both RARb2 and
CRBP1 loci.
Epigenetic Network Repression
PLoS ONE | www.plosone.org 2 February 2009 | Volume 4 | Issue 2 | e4305Evidence of CpG hypermethylation corroborates the
occurrence of heritable epigenetic silencing at both
RARb2 and CRBP1 consequent to deranged CRABP2
function
DNA hypermethylation is an epigenetic and heritable modifi-
cation. For this reason, we tested for DNA hypermethylation at
RARb2 and CRBP1 in HME1 cells with deranged CRABP2
function. First, we found that treatment of Si-CRABP2-A6 cells
with the demethylating agent 5-aza-29-deoxycitidine (5-Aza) could
significantly restore RA-induced RARb2 and CRBP1 transcription
(Fig. 4A, left and right). Then, we tested by quantitative
methylation specific PCR (qMSP) whether RARb2 and CRBP1
regulatory regions in the CRABP2 knock down clones were indeed
marked by DNA hypermethylation. For the detection of RARb2
methylated (M) alleles, we used primers previously shown to
Figure 1. Interference with RA transport into the nucleus is sufficient to induce transcriptional repression of genes downstream of
RARa. (A) WB analysis showing that HME1 cells express RARa (left). Immunoprecipitation (IP) followed by WB showing that HME1 express CRABP2. IP
of Hela cells transiently transfected with CRABP2-V5 served as positive control (right). (B) Transcriptional activation of two RA-responsive genes,
RARb2 and CRBP1, in response to RA (72 h) demonstrates a functional RA-RARa signaling in HME1 cells. (C) Transient HME1 transfection with wild
type CRABP2-V5, followed by immunocytochemistry with anti-V5 (red) and DAPI nuclear staining (blue), shows that exogenous CRABP2-V5 can
translocate from the cytoplasm into the nucleus after treatment with 0.1 mM RA for 30 min. (left). In contrast, exogenous CRABP2-KRK-V5 mutant
carrying a mutated nuclear localization signal (NLS) is not able to enter the nucleus under the same conditions (right). (D) WB analysis showing the
expression of the CRABP2-KRK-V5 protein in the HME1-derived clone KRK-15, but not in the HME1 control clone EV7. In vitro transcribed and
translated CRABP2-KRK-V5 was used as a positive control (left). Both KRK-15 and EV-7 cells express RARa (right). (E) Both RARb2 and CRBP1
transcription are significantly less inducible by RA (72 h) in KRK-15 cells relative to the control EV7 cells.
doi:10.1371/journal.pone.0004305.g001
Epigenetic Network Repression
PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e4305recognize the RARb2 methylation epicenter [9], while for CRBP1
we used primers recognizing the two regions, M1 and M2, within
the CRBP1 CpG island that we demonstrated previously to be the
first undergoing aberrant DNA methylation in cells with an
impaired RARa signaling [7]. This analysis clearly shows that
CRABP2 knock down clones A6 and C6 have significantly more
RARb2 and CRBP1 methylated (M) alleles relative to the control
clone Mock13 (Fig. 4B, left and right). The finding that RARb2
and CRBP1 silencing is associated with DNA hypermethylation, a
well-established hallmark of aberrantly repressed chromatin,
further reinforces our conclusion that the repressed state of
RARb2 and CRBP1 chromatin in cells with deranged CRABP2
function is heritable, and therefore epigenetic.
Derangement of CRABP2 function exerts a chromatin
repression effect branching downstream of RARb2
Wepreviouslydemonstrated in a mouseembryonic carcinoma cell
model that an endogenous dominant negative RARamutant, lacking
part of the E domain harboring the RA-binding domain, induced
concerted epigenetic repression of both RARb2 and CYP26A1,
encoding for a RA hydrolase involved in RA catabolism [8]. We
reproduced this finding also in human cells carrying an exogenous
dominant negative RARa mutant lacking the RA-binding domain
(Fig. S2). Here we show that hampering CRABP2 function leads to
significant CYP26A1 chromatin repression also in HME1 cells.
First, we found that impairment of CRABP2 function in HME1
cells by either CRABP2 knock down, or expression of the mutant
Figure 2. Evidence of chromatin repression at RA-responsive genes downstream of RARa consequent to CRABP2 knock-down. (A)
The HME1-derived stable clones Si-CRABP2-A6 and Si-CRABP2-C6, carrying two distinct CRABP2-targeting shRNA sequences (CARBP2-A and CRABP2-
C, respectively), display a significant decrease in CRABP2 transcript relative to the control clone Mock-13 (left). The level of RARa expression is similar
in Si-CRABP2-A6, Si-CRABP2-C6 and the control clone Mock13 (right). (B) Both RARb2 (left) and CRBP1 (right) are significantly less inducible by RA
(72 h) in Si-CRABP2-A6 and Si-CRABP2-C6 clones relative to the control Mock13 clone. (C) qChIP analysis with anti-acetyl histone H4 (Ac-H4) showing
that RARb2 (top) and CRBP1 (bottom) chromatin of both Si-CRABP2-A6 and Si-CRABP2-C6 is marked by H4 hypoacetylation at the RARE-containing
regulatory regions relative to the control clone Mock-13. (D) RA-induced RARb2 (top) and CRBP1 (bottom) transcription can be restored in Si-CRABP2-
A6 cells by treatment with the HDAC inhibitor TSA. (E) qChIP with anti-Polymerase II (Pol II) showing decreased occupancy of Pol II at the RARE-
containing regions of both RARb2 (top) and CRBP1 (bottom) in Si-CRABP2-A6 and Si-CRABP2-C6.
doi:10.1371/journal.pone.0004305.g002
Epigenetic Network Repression
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induced CYP26A1 transcription (Fig. 5A, left and right, respec-
tively). CYP26A1 transcription is driven by a promoter region
containing a proximal RARE at 287 and seems to be enhanced
by an upstream region containing a distal RARE at 21973
[16,17]. ChIP analysis with anti-acetyl histone H4 shows that
CYP26A1 downregulation in Si-CRABP2-A6 and Si-CRABP2-C6
clones is marked by histone deacetylation, which is unresponsive to
RA, both in the region containing the distal RARE (data not
shown) and in the region containing the proximal RARE (Fig. 5B,
left). Consistently, treatment with the HDAC inhibitor TSA could
efficiently restore RA-induced CYP26A1 transcription in CRABP2
knock down clones (shown here for Si-CRABP2-A6 in Fig. 5B,
right).
Second, we tested whether the CYP26A1 repressed chromatin
state, consequent to CRABP2 knock down, was also marked by
DNA hypermethylation. By in silico analysis of the 59 regulatory
regions of human CYP26A1, we identified two canonical CpG
islands: one encompassing the distal RARE, and one encompass-
ing the proximal RARE (Fig. S3). Bisulfite sequencing of these two
regions showed that the proximal CpG island is fully methylated in
the CYP26A1-negative cell line MDA-MB-231, while it is fully
unmethylated in two CYP26A1-positive cell lines, T47D and
HME1 (Fig. 5C, left). In contrast, the methylation status of the
distal CpG island did not show any significant difference between
HME1 and MDA-MB-231 (data not shown). Therefore, we
focused our analysis on the proximal CpG island. By using qMSP
with primers able to discriminate between the different methyl-
ation status of the control cell lines HME1, T47D and MDA-MB-
231 (Fig. 5C, right), we found that the CRABP2 knock down
clones have significantly more CYP26A1 methylated (M) alleles
relative to the control clone Mock13 (Fig. 5D, left). Consistently,
treatment with the demethylating agent 5-Aza could significantly
restore RA-induced CYP26A1 transcription in CRABP2 knock
down cells (shown here for Si-CRABP2-A6 in Fig. 5D, right).
Finally, we asked whether CYP26A1 epigenetic downregulation
is consequent to, or concomitant with, the epigenetic downregu-
lation of CRBP1, the other RARb2 target. We found that
CYP26A1 transcription is still RA-inducible in HME1 cells
knocked down for CRBP1 (Si-CRBP1) (Fig. 5E). Thus, CYP26A1
transcriptional downregulation, induced by hampering CRABP2
function, is consequent to a ‘‘long distance’’ repression effect,
branching downstream of RARb2, and involving both CRBP1 and
CYP26A1 chromatin (Fig. 6).
Discussion
In different cell systems, and using different mechanistic
approaches, we previously demonstrated that an impaired RARa
signalling, due to derangement/loss of RARa itself, confers an
Figure 3. Hampering CRABP2 function in HME1 cells leads to biological phenotypes that reflect homozygosis for epigenetically
silent RARb2 and CRBP1 alleles. (A) HME1 cells knocked down for RARb2 (Si-RARb2) develop resistance to RA growth-inhibitory action (left). The
HME1 clones KRK-15, Si-CRABP2-A6 and Si-CRABP2-C6, with impaired CRABP2 function, show a significantly higher fraction of RA-resistant cells than
the cognate control clones EV7 and Mock-13 (right). (B) Scheme showing that RA-resistance is expected only in cells homozygous for RARb2 alleles
non-permissive for transcription (np/np), but not in cells either homozygous for permissive RARb2 alleles (p/p), or heterozygous for permissive and
non-permissive RARb2 alleles (p/np). (C) HME1 cells knocked down for CRBP1 (Si-CRBP1, top left) are unable to form hollow, polarized acini in three-
dimensional (3D) culture, as shown by confocal fluorescence microscopy (nuclei are visualized in blue, integrin in green, and the Golgi apparatus in
red). HME1 clones with an impaired CRABP2 function (KRK15, Si-CRABP2-A6 and Si-CRABP2-C6) are also unable of proper acinar morphogenesis. (D)
Scheme showing that impaired acinar morphogenesis is expected only in cells that have developed homozygosis for non-permissive CRBP1 alleles.
doi:10.1371/journal.pone.0004305.g003
Epigenetic Network Repression
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epigenetic changes at several RA-responsive genes downstream of
RARa [7–9]. This study shows that hampering CRABP2, a factor
critical for RA transport onto nuclear RARa, in cells with a
functionally intact RARa, also leads to epigenetic repression of
RA-responsive genes downstream of RARa, with heritable
biological outcomes.
We provide evidence that derangement of CRABP2 function is
sufficient to trigger the coordinated repression of the RARa direct
target RARb2, and two RARb2 downstream targets, CRBP1 and
CYP26A1. Specifically, in HME1 cells with functional RARa,w e
observed that not only the silencing of endogenous CRABP2, but
the mere interference with CRABP2-mediated RA-transport into
the nucleus, achieved by expressing the CRABP2-KRK protein
with a mutated nuclear localization signal, induces heritable
epigenetic changes at genes of a RA-responsive gene network
downstream of RARa (Fig. 6).
Apparently, the abrogation of RARa function, be it due to
RARa silencing/genetic mutations, or derangement of a factor
upstream of RARa (e.g. CRABP2), results in the conversion of the
chromatin of RARa-regulated genes from an inactive, yet poised,
state permissive for transcription into an exacerbated repressed
state that is non permissive for transcription. We refer to the latter
state as the ‘‘state of no return’’, because it is marked by repressive
epigenetic modifications, which remain unresponsive to RA [9].
This exacerbated, repressed state is distinct from the physiological
repressed poised state, which is still responsive to RA. We still do
not know what molecular mechanism(s) is capable of ‘‘invoking’’
the recruitment of chromatin repressive activities at RA-responsive
genes downstream of RARa, once RARa function is impaired.
As a result of derangement of CRABP2 function, and
consequent impairment of RARa function, we found evidence
that cells develop homozygosis for epigenetically silent genes that
are either RA-receptors (RARb2) or RA-responsive genes involved
in both RA metabolism and morphogenesis (CRBP1 and
CYP26A1). Specifically, we demonstrated that the homozygous
epigenotypes for these repressed genes are heritable based on the
analysis of biological and morphological phenotypes in HME1
cells either carrying the dominant negative mutant CRABP2
protein, or knocked down for CRABP2. Even when RARa was still
expressed, we observed in a significant fraction of cells both RA
resistance, indicative of loss of RARb2 function, and aberrant
acinar morphogenesis, indicative of loss of CRBP1 function. The
RA-resistant phenotype and the aberrant acinar morphology is
expected to reflect only epigenotypes homozygous for repressed,
non-permissive RARb2 and CRBP1 alleles, respectively. Consis-
tently, in the same cells, we found evidence of aberrant CpG
methylation, an epigenetic hallmark of repressed chromatin, at
both RARb2 and CRBP1. The repressive repercussion due to
derangement of CRABP2 function affects also the chromatin of
CYP26A1, another RA-responsive gene downstream of both
RARa and RARb2. Downregulation of CYP26A1 transcription
is marked by both hypoacetylation unresponsive to RA and
hypermethylation of the CpG island containing the proximal
CYP26A1 RARE. Apparently, RARs and genes of the RA
metabolism (CRBP1 and CYP26A1), are part of the same
network. This RARa-regulated gene network is clearly implicated
also in cell growth and cell morphogenesis. Further, this gene
network can undergo concerted epigenetic repression as a
consequence of derangement of factor(s) capable of interfering
with RARa function.
In conclusion, this study reinforces the supposition that
epigenetic repression in cancer cells may result from an ordered,
rather than random, re-programming of the chromatin in
Figure 4. Evidence of CpG hypermethylation corroborates the occurrence of epigenetic silencing at both RARb2 and CRBP1
consequent to impaired CRABP2 function. (A) Treatment with the demethylating agent 5-Aza can restore RA-induced transcription from
repressed RARb2 and CRBP1 chromatin in Si-CRABP2-A6 cells (left and right, respectively). (B) Quantitative MSP detecting methylated (M) alleles shows
hypermethylation of RARb2 (left) and CRBP1 (right) CpG-rich regulatory regions in Si-CRABP2-A6 and Si-CRABP2-C6 clones.
doi:10.1371/journal.pone.0004305.g004
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that underlies development [18].
Materials and Methods
Cell cultures
Cells. The human immortalized, non-transformed breast
epithelial cell strain hTERT-HME1, here referred to as HME1,
was grown in Mammary Epithelial Growth Medium (MEGM)
plus bovine pituitary extract as per manufacturer’s instructions
(Lonza, Walkersville, MD). The HME1-derived clones knock
down for RARb2 and CRBP1 have been described in [7]. The
human breast cancer cell lines T47D and MDA-MB-231 (ATCC,
Manassas, VA), and the T47D-derived clones DNC8 and LXC5,
carrying the dominant negative RARa 403, or the cognate control
vector, respectively [9], were cultured in Dulbecco’s modified
Figure 5. Derangement of CRABP2 function exerts a chromatin repression effect branching downstream of RARb2. (A) RA-induced
transcription of CYP26A1 is significantly downregulated in both HME1 cells knocked down for CRABP2 (Si-CRABP2-A6 and Si-CRABP2-C6 clones, left),
and HME1 cells carrying the CRABP2-KRK mutant (KRK-15 clone, right) relative to control cells (Mock 13 and EV7 clones, respectively). (B) qChIP
analysis with anti-acetyl histone H4 showing that CYP26A1 chromatin in Si-CRABP2-A6 and Si-CRABP2-C6 clones is marked by a significant H4
hypoacetylation of a region encompassing the CYP26A1 proximal RARE (left). RA-induced CYP16A1 transcription can be restored in Si-CRABP2-A6 by
treatment with the HDAC inhibitor TSA for 72 h (right). (C) Bisulfite sequencing showing that HME1, like the CYP26A1-positive cell line T47D, is
unmethylated in the proximal RARE-containing CpG island, while the CYP26A1-negative cell line MDA-MB-231 is fully methylated (left). Quantitative
MSP with primers recognizing only methylated (M) alleles can detect methylation in MDA-MB-231, but not in T47D or HME1 cells (right). (D)
Quantitative MSP analysis showing hypermethylation of CYP2A1 proximal CpG island in Si-CRABP2-A6 and Si-CRABP2-C6 clones (left). RA-induced
CYP26A1 transcription can be efficiently restored in Si-CRABP2-A6 cells by treatment with the demethylating agent 5-Aza (right). (E) CYP26A1
transcription can still be induced by RA in HME1 cells knock down for CRBP1 (Si-CRBP1). Thus, CYP26A1 epigenetic downregulation is not consequent
to CRBP1 epigenetic silencing.
doi:10.1371/journal.pone.0004305.g005
Epigenetic Network Repression
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(Invitrogen, Carlsbad, CA). Cells were all maintained at 37uCi n
5% CO2 and 85% humidity.
Three dimensional (3D)-cultures. HME1 cells and derived
clones were grown on reconstituted basement membrane
(Matrigel) to induce breast epithelial differentiation into acini-
like structures, essentially as described [19]. Briefly, single cells
were induced to form acini on chamber slides coated with growth
factor-reduced Matrigel (BD Biosciences, San Jose, CA) in
medium plus 2% matrigel for 10–15 days. After fixation with
4% paraformaldehyde for 20 min, permeabilization with
Phosphate Buffered Saline (PBS) plus 0.1 % Triton X100 for
10 minutes, and blocking with PBS plus 1% BSA, 1% goat serum,
0.05 Tween 20 for 2 h, cells were incubated over night with both
an antibody specific for the Golgi apparatus (anti-GM 130, 1:400,
BD Biosciences), and an antibody for integrin (anti-CD49f, 1:200,
Chemicon, Temecula, CA), followed by detection with goat anti-
mouse Alexa Fluor 546 (1:400, Molecular Probes) and goat anti-
rat Alexa Fluor 488 (1:400, Molecular Probes, Eugene, OR).
Nuclei were counterstained with 300 nM DAPI (Sigma, St. Louis,
MO). 30 acini, or more, per each clone were analyzed by confocal
microscopy (SP2 Spectral Confocal Microscope, Leica, Wetzlar,
DE) to inspect for the presence of a hollow lumen and apicobasal
polarization. The morphology observed in 70% or more of the
acini was considered to be the prevalent phenotype.
Colony formation assay. Exponentially growing cells were
seeded at 3610
2 cells/well in 6-well plates and allowed to attach
for 48 h. After treatment with either 0.1 mM RA or vehicle
(ethanol) for 24 h, the medium was replaced with drug-free
medium and cells were allowed to grow until the appearance of
colonies was observed (10–14 days). Colonies fixed with methanol
and stained with Giemsa were analyzed with Image J software
(http://rsbweb.nih.gov/ij/) to establish the percentage of growth
compared to the non-treated control (colony formation index).
Statistical significance was calculated by Student’s t-test on three
independent determinations; p values at least ,0.05 were
considered as significant.
Transient transfections. Wild type (WT) CRABP2 was
amplified from pCMV-FLAG-CRABP2 plasmid DNA and
CRABP2-KRK was amplified from pSG5-CRABP2-KRK
plasmid DNA (kindly provided by Dr. Noa Noy, Case Western
Reserve University, Cleveland, OH) [13], by using specific primers
(sense: 59- GCC ACC ATG CCC TTC TCT-39; antisense: 59-
CTC TCG GAC GTA GAC CCT GG-39). Both WT-CRABP2
and CRABP2-KRK amplified products were cloned into
pcDNA3.1-V5/His TOPO vector (Invitrogen) in frame with the
V5-His tag at the 39 end, and sequenced. HME1 cells grown on
glass coverslips in 6-well plates for 24 h were transfected with
either pcDNA3.1-WT-CRABP2-V5 or pcDNA3.1-CRABP2-
KRK-V5 using Lipofectamine 2000 (Invitrogen) as per
manufacturer’s instructions. After 24 h cells were treated with
either RA (0.1 mM) or vehicle (ethanol) for 30 minutes, fixed in 4%
paraformaldehyde for 7 min., permeabilized with PBS plus 0.1%
Triton X100 for 5 min., blocked with PBS containing 1% BSA,
1% goat serum and 0.05% Tween 20, and incubated with anti-V5
antibody (1:200) (Invitrogen) as primary antibody for 1 h, rinsed,
and detected with an anti-mouse Alexa Fluor 546 secondary
antibody (1:400) (Invitrogen). After counterstaining with DAPI,
cells were mounted with Vectashield (Vector Laboratories), and
analyzed with a Fluorescence microscope (Axioskop, Zeiss).
Stable transfections. Cells were transfected with either
pcDNA3.1-CRABP2-KRK or the cognate empty vector (EV) by
using Lipofectamine 2000, and selected with 1mg/ml G-418
sulfate (Invitrogen). The presence of CRAPB2-KRK mutant was
tested both by PCR (sense primer: 59- GCC ACC ATG CCC
TTC TCT- 39; antisense primer: 59- CTC TCG GAC GTA GAC
CCT GG- 39) and Western Blotting in independent clones.
Stable RNA interference (RNAi). The sequences CRABP2-
A( 5 9- CTG ACC AAC GAT GGG GAA C-39), CRABP2-C (59-
GGT TGT CCC TGG ACT TGT C-39) (Gene Bank
NM_001878, nucleotides 477–495, and 9–27 respectively)
targeting CRABP2 mRNA, and the control mock sequence (59-
ACG TAC GTA CGT AGT GGG G-39), which does not
recognize any human mRNA, were cloned into the pSUPER-retro
Figure 6. Epigenetic repression of a pleiotropic gene network as a consequence of a defective RA transport onto RARa. (A) RA
transport onto RARa by CRABP2 enables the transcriptional activation of a RA-responsive gene network involved in retinol (ROH)-RA metabolism,
control of cell growth, and morphogenesis. (B) Interference with CRABP2-mediated RA transport onto RARa leads to epigenetic repression of this
gene network, with pleiotropic biological outcome.
doi:10.1371/journal.pone.0004305.g006
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Seattle, WA). The silencing efficiency of the short hairpin RNAs
(shRNAs) produced by these constructs was preliminary tested on
exogenous CRABP2 transiently cotransfected with the shRNAs in
COS cells as previously described [7]. The pSuper-CRABP2-A,
pSuper-CRABP2-C, and pSuper-Mock constructs were stably
transfected in HME1 cells by using Lipofectamine Plus
(Invitrogen). Single stable clones were selected in puromycin 1
mg/ml, tested for the presence of the correct construct by PCR and
sequencing, and further analyzed for the level of endogenous
CRABP2 transcript by Real Time RT-PCR.
Drugs and treatments
All-trans-retinoic acid (RA) (Sigma, St. Louis, MO), 5-aza-29-
deoxycitidine (5-Aza) (Sigma), Trichostatin A (TSA) (Sigma), and a
specific RARa antagonist ER50891 (a kind gift of Kouichi
Kikuchi, Discovery Research Laboratories, Ibaraki, Japan [20])
were dissolved and stored as described previously [9]. Drugs were
diluted in MEGM for HME1 cells and derived clones, or DMEM
plus 5% charcoal-stripped FBS (Invitrogen) for T47D cells and
derived clones. Cells were allowed to attach over night and treated
in the dark with different drug combinations as indicated in the
Results section. RA-treatment was performed for 24 h for colony
formation assays, and for 72 h for transcription assays, adding
fresh RA every 24 h. ER50891 treatment was for 24 h, while TSA
and 5-Aza treatments were for 72 h.
Protein Assays
SDS PAGE and Western Blot (WB). Proteins were resolved
by SDS-PAGE, blotted on nitrocellulose membrane, and
incubated with primary antibodies for GAPDH, RARa (both
from Santa Cruz Biotechnology, Santa Cruz, CA), or the V5 tag
(Invitrogen).The in vitro transcription/translation of CRABP2-V5
was performed using PROTEINscriptH II kit (Ambion, Austin,
TX) as per manufacturer’s instructions. Primary antibodies were
detected with appropriate HRP-conjugated secondary antibodies
(GE Healthcare, Piscataway, NJ) and followed by ECL (GE
Healthcare).
Immunoprecipitation (IP). 500 ml cell lysates (lysis buffer:
20 mM Hepes pH 8.0, 5mM EDTA, 150 mM NaCl, 0.5% Triton
X100, 0.05% Tween20 plus Complete protease inhibitor cocktail,
Roche) were pre-cleared with 40 ml proteinA/proteinG slurry (2/1
by vol.) (Sigma), then incubated over night with anti-CRABP2
antibody. CRABP2-antibody complexes were immunoprecipitated
by adding 40 ml proteinA/proteinG slurry (2/1 by vol.), washed,
eluted with Laemmli sample buffer and analyzed by Western blot.
Real time RT-PCR
Total RNA was obtained using Trizol (Invitrogen), treated with
DNase I (Ambion, Austin, TX) and retrotranscribed with
SuperScript First-Strand Synthesis System (Invitrogen). cDNA
was amplified by Real-time RT-PCR on an iCycler (Bio-Rad,
Hercules, CA) by using the iQ SYBR Green Supermix (Bio-Rad)
and specific primers for CRABP2 (sense 59- TTG AGG AGC AGA
CTG TGG ATG-39, antisense 59- TTG GTC AGT TCT CTG
GTC CAC-39), RARb2 (sense: 59- GAC TGT ATG GAT GTT
CTG TCA G-39; antisense: 59- ATT TGT CCT GGC AGA
CGA AGC A-39), CRBP1 (sense: 59- GGT ACT GGA AGA TGT
TGG TC-39, antisense 59- CAT CTC TAG GTG CAG CTC
AT-39), CYP26A1 transcript variants 1 and 2 (sense: 59- GCA ATC
TTC AAC CGA ACT CC-39; antisense: 59- CTC CTT AAT
AAC ACA CCC GAT G-39), and GAPDH (sense: 59- GAA GGT
GAA GGT CGG AGT C-39; antisense: 59- GAA GAT GGT
GAT GGG ATT TC-39). The level of the different transcripts was
normalized to the level of the GAPDH transcript, and quantified by
the threshold cycle Ct method. Statistical significance was
calculated by Student’s t-test on three independent determinations;
p values at least ,0.05 were considered as significant.
Quantitative chromatin immunoprecipitation (qChIP)
ChIP was performed using reagents purchased from Upstate
(Lake Placid, NY), according to the manufacturer’s protocol.
Chromatin was immunoprecipitated with antibodies against either
acetyl-histone H4 or Polymerase II (both from Upstate), and DNA
amplification was carried out by real time-PCR with specific
primers encompassing the RARb2 RARE [9] (sense: 59- GGT
TCA CCG AAA GTT CAC TCG CAT-39; antisense: 59-
CAGGCTTGCTCGGCCAATCCA-39), the CRBP1 RARE [7]
(sense 59- AGC CTG CAC TGT GAG AAC ACA T-39, antisense
59- CCA CCA AGT AGA TGA CAT AAT CA-39), the proximal
CYP26A1 RARE (P-RARE) (sense 59- GGA GCT CAG CAC
ACC TTG GAT-39 and antisense 59- CCA GGT TGC TGC
CCA CGT TA-39), or the distal CYP26A1 RARE (D-RARE)
(sense 59- GAG TTC ACT CGG ATG TCA CGG-39 and
antisense 59- CTT TCT GGA CAG CGC CTC CG-39). The
relative enrichment of immunoprecipitated DNA was calculated
by normalizing the PCR signals of the samples to both the input
and the no antibody controls. Amplification of the GAPDH
promoter region (sense: 59- GGT GCG TGC CCA GTT GAA
CCA-39; antisense: 59- AAA GAA GAT GCG GCT GAC TGT
CGA A-39) was used as an internal control. Statistical significance
was calculated by Student’s t-test on three independent determi-
nations; p values at least ,0.05 were considered as significant.
DNA methylation analysis
Genomic DNA was extracted with DNAzol (Invitrogen)
according to the manufacturer’s instructions. DNA was modified
by sodium bisulfite treatment as previously described [21] and
used for either bisulfite sequencing or quantitative Methylation
Specific PCR (qMSP) by real time PCR with iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA) on an iCycler (Bio-Rad). For
RARb2 qMSP we used a previously described primer set (M4 sense
59- GTC GAG AAC GCG AGC GAT TC-39 and M4 antisense
59- CGA CCA ATC CAA CCG AAA CG-39) [9,11]. For CRBP1
qMSP we used the following primers, specifically amplifying two
methylated CRBP1 regions: M1 sense 59- CGT TTT TGC GTT
CGT TTT CGT TAA GC-39 and AS1 antisense 59- AAA TAA
CTA AAA CCA ATT AAC CAC AAA-39; M2 sense 59- CGT
TGC GTT TTG GGC GTT TCG TC-39 and AS2 antisense 59-
CAC CAA ACC ACA ACT CAC CAA A-39. For CYP26A1, the
59 region of the gene was first analyzed for the presence of
canonical CpG Islands by using CpG Island Searcher (http://
cpgislands.usc.edu/). For bisulfite sequencing of the CpG island
containing the proximal RARE, bisulfite modified DNA was
amplified by nested PCR with Platinum Taq (Invitrogen). The first
PCR round was performed with the following primers: P772 sense
59- TAT TAY GTG GAA GAG AGT TTA T-39 and P773
antisense 59- ACT TCA ACA AAA ACC CAA AAC-39. The
second PCR round was performed with the following primers:
P776 sense 59GAA GGT TAG AGT TTG GAA TTT-39 and
P775 antisense 59- CCT ACA ATA CCA TCT ACA AAA-39.
The PCR product was gel-purified and sequenced. For qMSP of
the proximal CpG island, bisulfite modified DNA was amplified by
nested PCR. The first PCR round was performed as described for
bisulfite sequencing. The second round was performed by real
time PCR with iQ SYBR Green Supermix (Bio-Rad) in
combination with primers specific for methylated CpGs (P764
sense 59- TCG GCG CGG AAT AAA CGG T-39 and P765
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PCR signal from the M alleles was normalized to the signal from a
control CYP26A1 region amplified by using primers that do not
recognize any CpG (P774 sense: 59- TTA GTG AAG GTT GTT
TTG GGT-39 and 59- AAT ACA AAT CCC AAA ACT TAA-
39). Statistical significance was calculated by Student’s t-test on
three independent determinations; p values at least ,0.05 were
considered as significant.
Supporting Information
Figure S1 Development of CRABP2 knock down clones. (A)
Scheme of the short hairpin (sh) RNA sequences cloned into the
pSUPER vector and subsequently used for HME1 stable
transfection (left). Transient co-transfection experiments followed
by WB analysis showing that the CRABP2-targeting sequences
CRABP2-A and CRABP2-C, but not the scrambled sequence
Mock, can effectively decrease the protein level of exogenous
CRABP2 (right). (C) Sequencing analyses showing that the stable
clones Si-CRABP2-A6, Si-CRABP2-C6 and Mock-13 contain the
correct p-SUPER construct.
Found at: doi:10.1371/journal.pone.0004305.s001 (0.76 MB
DOC)
Figure S2 CYP26A1 downregulation in human cells with an
impaired RA-RARa signaling is marked by epigenetic chromatin
changes. (A) Hampering RA availability at RARa by treatment
with the RARa-specific antagonist ER50891 can significantly
antagonize RA-induced transcription of both RARb2 (top) and
CYP26A1 (bottom) in human cells (T47D). (B) T47D cells stably
expressing a RARa dominant negative protein (DNC8), and
cognate control cells (LXC5), are CRABP2-positive (top). (C)
Impairment of RARa function in DNC8 cells significantly
downregulates RA-induced transcription of both RARb2 (left)
and CYP26A1 (right) relative to control LXC5 cells. (D) CYP26A1
transcriptional repression in DNC8 cells is associated with
significant histone H4 hypoacetylation, unresponsive to RA, at
the CYP26A1 regions encompassing either the distal RARE (D-
RARE), or the proximal RARE (P-RARE). (E) Treatment of
DNC8 cells with either TSA (24 h), or 5- Aza (72 h) can restore
RA-induced transcription from both RARb2 (left) and CYP26A1
(right).
Found at: doi:10.1371/journal.pone.0004305.s002 (3.50 MB TIF)
Figure S3 In silico identification of human CYP26A1 CpG
islands. Analysis of the CYP26A1 59 regulatory regions by using
CpG Island Searcher identifies two CpG islands: one containing
the distal RARE (D-RARE), from 22086 to 21502, and one
containing the proximal RARE (P-RARE), from 2375 to +2239.
Found at: doi:10.1371/journal.pone.0004305.s003 (9.31 MB TIF)
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